Lycia Therapeutics: director Jane Henderson received 77,666 shares

What happened

• Jane Henderson, a director, received awards for 57,666 and 20,000 derivative shares at $0.00, for a total of 77,666 shares, as reported in the Form 4 filing. The filing shows total value of the reported transactions as $0.

Key details

• Transaction dates and prices: Aug 11, 2026 — 57,666 shares at $0.00 (derivative); Oct 22, 2026 — 20,000 shares at $0.00 (derivative).
• Shares owned following the reported transactions: not specified in the provided filing information.
• Filing date: Oct 26, 2026. The filing reports transactions dated Aug 11, 2026 and Oct 22, 2026; the filing was submitted after those dates (late).
• Footnotes from the filing:
  • F1: The Aug 11, 2026 transaction occurred prior to the issuer's registration of a class of equity securities in connection with the initial public offering and is reported under Rule 16a-2(a).
  • F2: The 57,666-share award vests 1/48 of the total award monthly over four years, with the first tranche vested on Aug 6, 2026, subject to continued service.
  • F3: The 20,000-share award will vest 100% on Oct 22, 2027, subject to continued service.

Why it may matter

• These were awards/grants of derivative securities (not open-market purchases or sales); vesting is time-based per the footnotes.
• The filing does not show why the insider traded or why the company acted.